噻唑烷二酮类药物用于2型糖尿病患者的心血管安全性评价

TZDS Drugs Used in Cardiovascular Safety Evaluation of Patients with Type 2 Diabetes

噻唑烷二酮类药物(thiazolidinediones,TZDs)是人工合成的PPARγ的高选择性配体,TZDs与PPARγ结合可以启动下游的基因转录,进而改善胰岛素抵抗,降低血糖。作为经典的胰岛素增敏剂,TZDs主要用于2型糖尿病的治疗。此类药物曾因增加心血管事件及膀胱癌风险被禁用或限用,后又因证据不足被解禁,近年来有大型临床研究及Meta分析指出,TZDs类药物不增加心血管不良事件风险,且有潜在的心血管保护作用。

Thiazolidinediones（TZDs）are synthetic PPAR-7 selective ligands, insulin-sensitizing agents used in the treatment of type 2 diabetes. They were once restricted to use for the possibility that TZDs drugs could increase the risk of cardiovascular adverse events, while then was released for insufficient evidences.In recent years, there were large clinical studies and Meta analysis pointed out TZDs drugs did not increase the risk of cardiovascular adverse events, but has potential cardiovascular protection.